- Home
- SVII vs GNFT Comparison
SVII vs GNFT Comparison
Compare SVII & GNFT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SVII
- GNFT
- Stock Information
- Founded
- SVII 2021
- GNFT 1999
- Country
- SVII United States
- GNFT France
- Employees
- SVII N/A
- GNFT N/A
- Industry
- SVII Blank Checks
- GNFT Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- SVII Finance
- GNFT Health Care
- Exchange
- SVII Nasdaq
- GNFT Nasdaq
- Market Cap
- SVII 248.9M
- GNFT 249.0M
- IPO Year
- SVII 2022
- GNFT 2019
- Fundamental
- Price
- SVII $11.30
- GNFT $5.59
- Analyst Decision
- SVII
- GNFT Strong Buy
- Analyst Count
- SVII 0
- GNFT 1
- Target Price
- SVII N/A
- GNFT $13.00
- AVG Volume (30 Days)
- SVII 9.2K
- GNFT 21.1K
- Earning Date
- SVII 01-01-0001
- GNFT 09-19-2024
- Dividend Yield
- SVII N/A
- GNFT N/A
- EPS Growth
- SVII 36.87
- GNFT N/A
- EPS
- SVII 0.37
- GNFT 0.47
- Revenue
- SVII N/A
- GNFT $86,225,222.00
- Revenue This Year
- SVII N/A
- GNFT $155.44
- Revenue Next Year
- SVII N/A
- GNFT N/A
- P/E Ratio
- SVII $30.53
- GNFT $11.74
- Revenue Growth
- SVII N/A
- GNFT 175.45
- 52 Week Low
- SVII $10.72
- GNFT $2.97
- 52 Week High
- SVII $11.32
- GNFT $6.05
- Technical
- Relative Strength Index (RSI)
- SVII 71.27
- GNFT 62.71
- Support Level
- SVII $11.20
- GNFT $5.12
- Resistance Level
- SVII $11.23
- GNFT $5.84
- Average True Range (ATR)
- SVII 0.01
- GNFT 0.32
- MACD
- SVII 0.01
- GNFT 0.02
- Stochastic Oscillator
- SVII 80.00
- GNFT 60.94
About SVII Spring Valley Acquisition Corp. II
Spring Valley Acquisition Corp II is a blank check company.
About GNFT GENFIT S.A.
Genfit SA is a biotechnology company focused on metabolic and inflammatory diseases, with a particular focus on the liver and gastroenterology. The company's research and development activity relies on its expertise in modulating gene expression through nuclear receptors. Genfit utilizes acquisitions, strategic alliances, and licensing agreements in order to fund the further development of its products. It has one segment the research and development of innovative medicines and diagnostic solutions, the marketing of which depends on the success of the clinical development phase.